11 ANNEX XI COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OF MARKERS OF TREPONEMA PALLIDUM INFECTION, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

This Annex applies to devices intended for detection of markers of Treponema pallidum (T. pallidum).

Table 1 applies to first-line assays for antibodies against T. pallidum (anti-T.pallidum).

Table 2 applies to confirmatory and supplemental anti-T.pallidum assays.

Table 1. First-line assays: anti-T.pallidum

[Blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first-time donors.]

Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria

Diagnostic

sensitivity

Positive specimens |

≥200 positive specimens in total,

at different stages of the infection if available,

including high positive and low positive specimens,

identified as positive by at least two different serological tests (one of which is an enzyme immunoassay) for different antibodies to T.pallidum

≥99.5% overall sensitivity

Seroconversion panels | At least 1 seroconversion panel, ≥1 if possible, including individual specimens from the early infection phase | Diagnostic sensitivity during seroconversion shall represent the state of the art.

Analytical

sensitivity

Standards |

WHO international standards

NIBSC code 05/132, when available

Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥5000 | ≥99,5%

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥100 in total

including the following specimens: positive for Borrelia burgdorferi sensu lato confirmed by IgG immunoblot; anti-HIV positive; RF+; other related microbial/infectious agents; systemic lupus erythematosus (SLE) patients; antiphospholipid antibody positive; pregnant women etc.

Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥300 positive specimens at different stages of the infection (early primary syphilis, secondary stage, and during late syphilis ) including high positive specimens, 50 low positive specimens,

by at least two different serological tests (one of which is an enzyme immunoassay) for different antibodies to T.pallidum

99% identification as “confirmed positive” or “indeterminate”

Seroconversion panels | At least 1 seroconversion panel, ≥1 if possible, including individual specimens from the early infection phase | Diagnostic sensitivity during seroconversion shall represent the state of the art

Analytical sensitivity | Standards |

WHO international standards

NIBSC code 05/132

Diagnostic specificity | Blood donors | ≥200 | ≥ 99%;

Clinical specimens | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens | ≥50 in total, including specimens from pregnant women and specimens with indeterminate results in other confirmatory assays.